BrainsWay Ltd. (NASDAQ: BWAY) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 30.93 | EPS (ttm) | 0.44 | Insider Own | 0.25% | Shs Outstand | 39.22M | Perf Week | -2.30% |
| Market Cap | 533.83M | Forward P/E | 26.86 | EPS next Y | 0.51 | Insider Trans | -23.80% | Shs Float | 29.42M | Perf Month | -10.28% |
| Enterprise Value | 478.83M | PEG | 0.95 | EPS next Q | 0.12 | Inst Own | - | Short Float | 0.71% | Perf Quarter | -8.60% |
| Income | 10.00M | P/S | 8.61 | EPS this Y | -30.30% | Inst Trans | - | Short Ratio | 1.74 | Perf Half Y | -2.30% |
| Sales | 62.00M | P/B | 6.76 | EPS next Y | 65.22% | ROA | 7.76% | Short Interest | 208.11K | Perf YTD | 43.11% |
| Book/sh | 2.01 | P/C | 8.61 | EPS next 5Y | 32.70% | ROE | 12.69% | 52W High | 17.40 -21.78% | Perf Year | 69.49% |
| Cash/sh | 1.58 | P/FCF | 103.21 | EPS past 3/5Y | - | ROIC | 7.71% | 52W Low | 7.14 90.62% | Perf 3Y | 616.32% |
| Dividend Est. | - | EV/EBITDA | 39.90 | Sales past 3/5Y | 24.42% 18.77% | Gross Margin | 75.33% | Volatility | 3.39% 3.28% | Perf 5Y | 237.72% |
| Dividend TTM | - | EV/Sales | 7.72 | EPS Y/Y TTM | 388.89% | Oper. Margin | 12.18% | ATR (14) | 0.59 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.27 | Sales Y/Y TTM | 51.22% | Profit Margin | 14.61% | RSI (14) | 39.03 | Recom | 2.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | EPS Q/Q | 180.00% | SMA20 | -3.54% | Beta | 1.26 | Target Price | 19.50 |
| Payout | 0.00% | Debt/Eq | 0.08 | Sales Q/Q | 30.77% | SMA50 | -8.85% | Rel Volume | 0.42 | Prev Close | 13.53 |
| Employees | 129 | LT Debt/Eq | 0.08 | Earnings | Nov 10 | SMA200 | 0.55% | Avg Volume | 113.01K | Price | 13.61 |
| IPO Date | Apr 17, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 90.91% 3.42% | Net Debt/EBITDA | -8.04 | Volume | 47,196 | Change | 0.59% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-31-26 | Reiterated | HC Wainwright & Co. | Buy | $14 → $19 |
| Aug-12-26 | Reiterated | BTIG | Buy | $18 → $20 |
| Jul-20-26 | Initiated | BTIG | Buy | $18 |
| Jul-17-26 | Reiterated | H.C. Wainwright | Buy | $17 → $14 |
| May-26-26 | Reiterated | HC Wainwright & Co. | Buy | $30 → $17 |
| Jan-26-26 | Reiterated | HC Wainwright & Co. | Buy | $24 → $30 |
| Jan-22-26 | Reiterated | Northland Securities | Outperform | $23 → $30 |
| Dec-08-25 | Reiterated | HC Wainwright & Co. | Buy | $16 → $24 |
| May-09-24 | Reiterated | Oppenheimer | Outperform | $11 |
| May-09-24 | Reiterated | HC Wainwright & Co. | Buy | $16 → $15 |
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 62 | 52 | 41 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 14 | 13 | 10 | — | — | — | — | — | — | |
| Gross Profit | 46 | 39 | 31 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 28 | 25 | 22 | — | — | — | — | — | — | |
| Research and Development | 11 | 10 | 7 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 7 | 4 | 1 | — | — | — | — | — | — | |
| Interest Expense | 2 | 2 | 1 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 6 | 3 | — | — | — | — | — | — | |
| Net Income Before Taxes | 10 | 8 | 3 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | 10 | 8 | 3 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 10 | 8 | 3 | — | — | — | — | — | — | |
| Net Income | 10 | 8 | 3 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.46 | 0.40 | 0.09 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.46 | 0.40 | 0.09 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.44 | 0.36 | 0.09 | — | — | — | — | — | — | |
| EBITDA | 12 | 11 | 5 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 30.93 | 26.42 | 52.44 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.39 | 3.47 | 3.91 | — | — | — | — | — | — | |
| Gross Margin | 74.19 | 75.00 | 75.61 | — | — | — | — | — | — | |
| Operating Margin | 11.29 | 7.69 | 2.44 | — | — | — | — | — | — | |
| Net Margin | 16.13 | 15.38 | 7.32 | — | — | — | — | — | — | |
| Shares Outstanding | 20 | 19 | 34 | — | — | — | — | — | — | |
| Market Capitalization | 272 | 181 | 160 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Moiseyev Gilad | Chief Technology Officer | Jun 15 '26 | Sale | 0.00 | 5,000 | 0 | 53,098 | Jun 22 |
| Moiseyev Gilad | Chief Technology Officer | May 25 '26 | Option Exercise | 0.00 | 7,500 | 0 | 60,000 | Jun 22 |
| Mitrany Rayten Michal Ety | Director | May 26 '26 | Sale | 0.00 | 7,980 | 0 | 12,500 | May 26 |
| Mitrany Rayten Michal Ety | Director | May 25 '26 | Sale | 0.00 | 10,000 | 0 | 20,480 | May 26 |
| Mitrany Rayten Michal Ety | Director | May 20 '26 | Option Exercise | 0.00 | 17,500 | 0 | 36,560 | May 21 |
| Mitrany Rayten Michal Ety | Director | May 19 '26 | Option Exercise | 0.00 | 10,000 | 0 | 22,500 | May 21 |